

APCDE 2011

# Non-compaction & Other Unusual Cardiomyopathies

Dae-Hee Kim, MD, PhD  
College of Medicine  
University of Ulsan  
Asan Medical Center

# Historical context

- **1957** : the term “ **Cardiomyopathy**” for the first time ; **primary myocardial disease**
- **1968 (WHO)**: “Diseases of different and often unknown etiology in which the dominant feature is cardiomegaly and heart failure”
- **1980 (WHO)** : “Heart muscle diseases of unknown cause”

# Classification (1)

- 1995 WHO/ISFC definition & classification
  - Diseases of the myocardium associated with cardiac dysfunction
  - Dilated cardiomyopathy
  - Hypertrophic cardiomyopathy
  - Restrictive cardiomyopathy
  - Arrhythmogenic right ventricular cardiomyopathy
  - Unclassified cardiomyopathies

# Classification (2)

## Cardiomyopathies

### HCM

#### Familial

- Sarcomere protein mutation
- Storage disease
- Disorders of fatty acid metabolism
- Carnitine deficiency
- Phosphorylase B kinase deficiency
- Mitochondrial cytopathies
- Syndromic HCM
- Others

#### Non-familial

- Obesity
- Infants of diabetic mothers
- Athletic training
- Amyloid (AL/prealbumin)

### DCM

#### Familial

- Sarcomere protein mutation
- Z-band
- Cytoskeletal genes
- Nuclear membrane
- Mildly dilated CM
- Intercalated disc protein mutations (see ARVC)
- Mitochondrial cytopathy

#### Non-familial

- Myocarditis
- Kawasaki disease
- Eosinophilic (Churg Strauss syndrome)
- Viral persistence
- Drugs
- Pregnancy
- Endocrine
- Nutritional
- Alcohol
- Tachycardia myopathy

### ARVC

#### Familial

- Intercalated disc protein mutations
- Cardiac ryanodine receptor (RyR2)
- Transforming growth factor- $\beta$ 3 (TGF $\beta$ 3)

#### Non-familial

- Inflammation

### RCM

#### Familial

- Sarcomeric protein mutations
- Familial amyloidosis
- Desminopathy
- Pseudoxanthoma elasticum
- Haemochromatosis
- Anderson-Fabry disease
- Glycogen storage disease

#### Non-familial

- Amyloid (AL/prealbumin)
- Scleroderma
- Endomyocardial fibrosis
- Carcinoid heart disease
- Metastatic cancers
- Radiation
- Drugs (anthracyclines)

### Unclassified

#### Familial

- Left ventricular non-compaction
  - Barth syndrome
  - Lamin A/C
  - ZASP
  - $\alpha$ -dystrobrevin

#### Non-familial


- Tako Tsubo cardiomyopathy



# Agenda


- **LV non-compaction cardiomyopathy**
- **Arrhythmogenic RV cardiomyopathy**
- **Stress-induced cardiomyopathy**

# Non-Compaction Cardiomyopathy




# Noncompaction cardiomyopathy

- **Compaction** of the ventricular myocardium normally progresses from **epicardium to endocardium** and **from the base of the heart toward the apex** : 5-8 weeks of fetal development




- Arrest of compaction, **non-compaction** of normal myocardium: result in persistence of the deep recesses and sinusoids




# Noncompaction cardiomyopathy

- Segments of noncompacted myocardium mainly involve the apex and the inferior mid and lateral mid of the left ventricular wall





	Pediatric patients	Adult patients	
	Ichida [21]	Oechslin [31]	Sengupta [36]
LV apex	100%	94%	100%
LV inferior wall	70%	94%	95%
LV lateral wall	41%	100%	100%
Basal segments of the LV wall		< 20%	< 27%



# Diagnostic Criteria of LV Non-compaction

- Appearance of at least **four** prominent trabeculations and deep intertrabecular recesses
- **Endsystolic** noncompaction/compaction ratio (maximal thickness site)  $\geq 2$
- Deep recesses filled with blood from the ventricular cavity visualized by color Doppler imaging






MI:1.7  
S4 2.1/4.2  
11 JUNE 01  
15:31:03  
PROC 2/0/E/FB  
ASRN MEDICAL  
CENTER  
VOL-BP

0:41:49.29  
GAIN 59  
COMP 61  
73BPM  
14CM  
30HZ<sup>2</sup>


2.1 4.2



MI:1.6  
S4  
11 JUNE 01  
15:27:39  
PROC 2/0/E/F3  
ASRN MEDICAL  
CENTER  
VOL-BP

0:39:13.05  
GAIN 59  
COMP 61  
69BPM  
16CM  
62HZ<sup>2</sup>


P 2 R 4



MI:1.7  
S4 2.1/4.2  
11 JUNE 01  
15:31:29  
PROC 2/0/E/FB  
ASRN MEDICAL  
CENTER  
VOL-BP

0:42:15.18  
GAIN 59  
COMP 61  
79BPM  
13CM  
30HZ<sup>2</sup>


2.1 4.2




MI:1.7  
S4 2.1/4.2  
11 JUNE 01  
15:31:55  
PROC 2/0/E/FB  
ASRN MEDICAL  
CENTER  
VOL-BP

0:42:41.18  
GAIN 59  
COMP 61  
69BPM  
14CM  
30HZ<sup>2</sup>

2.1 4.2



# Fireworks in the Left Ventricle: Doppler Manifestation of Left Ventricular Noncompaction



- Deep recesses filled with blood from the ventricular cavity visualized by color Doppler imaging

*Kim et al. JACC 2009*

# Prevalence of Left Ventricular Noncompaction

- True prevalence : unclear, selection bias
- A review from Switzerland identified 34 cases in 15 years
- Prevalence: 0.014% of patients referred to Echo lab  
*Oechslin et al. JACC 2000*

- Male predominance
- 3.7% prevalence for LVEF <45%

*Sandhu et al. Echocardiography 2007*

- Association with facial dysmorphism & NMD



# Left Ventricular Noncompaction

- LVNC is associated with Neuromuscular diseases : as many as 82% of patients
- 62 patients with LVNC underwent neurological evaluation
  - Metabolic myopathy
  - Myotonic, Becker, Duchenne : (43%)
  - NMD of unknown etiology (39%)
  - Neurologically normal (18%)

*Stollberger et al. AJC 2002*



# Clinical presentation

- Heart failure
- Thromboembolic event
- Arrhythmias : VT, AF

Characteristics	Pediatric patients		Adult patients			
	Chin [9]	Ichida [21]	Oechslin [31]	Sengupta [36]	Murphy [30]	Stollberger [39]
Number of patients	8	27	34	32	45	62
Age at diagnosis (median)	7 yrs	5 yrs	40 yrs	49 yrs	37 yrs (mean)	50 yrs (mean)
Male	63%	56%	74%	53%	62%	79%
Familial occurrence	50%	44%	18%			
Follow-up	up to 5 yrs	up to 17 yrs	up to 11 yrs		up to 15 yrs	up to 6 yrs
ECG						
Bundle branch block	25%	15%	56%		29%	23%
WPW-syndrome	13%	15%	0%			3%
Ventricular tachycardia	38%	0%	41%		20% a	18%
Clinical symptoms						
Heart failure symptoms	63%	30%	68%	62.50%	62%	73%
Systemic embolic events	38%	0%	21%		4%	
Pulmonary embolism	0%	7%	9%			
Ventricular thrombi	25%	0%	9%	6%		
Facial dysmorphism	38%	33%	0%			
Neuromuscular disorders						82%
Deaths	38%	7%	35%		2%	
Heart transplantation	0%	4%	12%			

# MYH7 mutations in familial NCCM

*Hoedemaekers et al., EHJ, 2007*



*Could other known cardiomyopathy genes be involved in NCCM ????*

# Gene mutations in LVNC

Gene	Disease	Location	Child/adult
$\alpha$ -Dystrobrevin (DTNA)	LVNC with CHD, muscular dystrophy in human	18q12	Child
G4.5 (TAZ)	Barth syndrome, LVNC, DCM, EFE	Xq28	Child
LIM domain binding protein (LDB3, Cypher/ZASP)	LVNC, DCM	10q22-q23.2	Child/adult
Lamin A/C	LVNC, DCM, muscular dystrophy in human	1q22	Child/adult
<b>Sarcomere proteins</b>			
$\beta$ -myosin heavy chain (MYH7)	HCM, DCM, LVNC	14q11.2-q13	Adult
$\alpha$ -cardiac actin (ACTC)	HCM, DCM, LVNC	15q11-q14	Adult
Cardiac troponin T (TNNT2)	HCM, DCM, LVNC	1q32	Adult


*LVNC, left ventricular noncompaction; CHD, congenital heart disease; DCM, dilated cardiomyopathy; EFE, endocardial fibroelastosis; HCM, hypertrophic cardiomyopathy*

# Prognosis

- In a series of 34 adults with LVNC, 47% either died or underwent cardiac transplantation during the follow-up period of  $44 \pm 39$  months *Oechslin et al. JACC 2000*

- Nearly 60% of patients described in one large series had either died or undergone cardiac transplantation within 6 years of diagnosis *Ritter et al. Mayo Clin Proc. 1997*

# Arrhythmogenic RV Cardiomyopathy





# Arrhythmogenic RV dysplasia


- Pathologic hallmark of ARVD is RV myocyte loss with fibrofatty replacement
- Over the past decade, mutations in several **desmosomal** proteins have been identified as the genetic basis
- Defective desmosomal proteins may lead to impaired mechanical coupling between individual cells, leading to myocyte detachment and degeneration
- RV cavity dilation, ventricular wall thinning with aneurysms, and systolic dysfunction.



# Arrhythmogenic RV Dysplasia



**cadherins, desmoglein, desmocollin**





# Genetic factors

- Comprehensive mutation screening of all known and candidate genes is liable to yield a success rate of at least 40% in ARVD/C
- Lack of an identifiable mutation does not rule out disease
- Mutations were subsequently identified in desmoplakin, desmoglein-2, desmocollin-2, and plakophilin-2 genes
- Several extra-desmosomal genes, such as those encoding TGF- $\beta$ 3, cardiac ryanodine receptor (RyR2), and transmembrane protein 43 (TMEM43), have also been implicated in specific types

# Desmosomal Genes Implicated in AVRDC

Gene (Symbol), Locus	Exons (n), Transcript Size (kb)	Mode of Inheritance	Number of Reported Mutations	Type of Reported Mutations	Associated Phenotype
Plakoglobin (JUP) 17q21	14, 2.4	AR	1	Deletion	Naxos disease
Desmoplakin (DSP) 6p24	24, 8.9	AD AR	>10 3	Various Missense Nonsense Deletion	ARVC ARVC, skin disorder, woolly hair ARVC, skin disorder, woolly hair Carvajal syndrome
Plakophilin (PKP)-2 12p11	14, 2.6	AD AR	>50 1	Various Cryptic splice site	ARVC ARVC
Desmoglein (DSG)-2 18q12	15, 3.4	AD	>20	Various	ARVC
Desmocollin (DSC)-2 18q12	17, 3.1	AD	3	Deletion, insertion, splice site	ARVC

# Revised task force criteria for diagnosing arrhythmogenic right ventricular dysplasia

Diagnostic feature	Major criteria	Minor criteria
Global or regional ventricular dysfunction and structural alterations	<p><b>By 2D echo:</b></p> <ul style="list-style-type: none"> <li>•Regional RV akinesia, dyskinesia, or aneurysm and 1 of the following (end diastole):               <ul style="list-style-type: none"> <li>-PLAX RVOT <math>\geq 32</math> mm (corrected for body size [PLAX/BSA] <math>\geq 19</math> mm/m<sup>2</sup>)</li> <li>-PSAX RVOT <math>\geq 36</math> mm (corrected for body size [PSAX/BSA] <math>\geq 21</math> mm/m<sup>2</sup>)</li> <li>-or fractional area change <math>\leq 33\%</math></li> </ul> </li> </ul> <p><b>By MRI:</b></p> <ul style="list-style-type: none"> <li>•Regional RV akinesia or dyskinesia or dyssynchronous RV contraction</li> <li>•and 1 of the following:               <ul style="list-style-type: none"> <li>-Ratio of RV end-diastolic volume to BSA <math>\geq 110</math> mL/m<sup>2</sup> (male) or <math>\geq 100</math> mL/m<sup>2</sup> (female)</li> <li>-or RV ejection fraction <math>\leq 40\%</math></li> </ul> </li> </ul> <p><b>By RV angiography:</b></p> <ul style="list-style-type: none"> <li>•Regional RV akinesia, dyskinesia, or aneurysm</li> </ul>	<p><b>By 2D echo:</b></p> <ul style="list-style-type: none"> <li>•Regional RV akinesia or dyskinesia</li> <li>•and 1 of the following (end diastole):               <ul style="list-style-type: none"> <li>-PLAX RVOT <math>\geq 29</math> to <math>\leq 32</math> mm (corrected for body size [PLAX/BSA] <math>\geq 16</math> to <math>\leq 19</math> mm/m<sup>2</sup>)</li> <li>-PSAX RVOT <math>\geq 32</math> to <math>\leq 36</math> mm (corrected for body size [PSAX/BSA] <math>\geq 18</math> to <math>\leq 21</math> mm/m<sup>2</sup>)</li> <li>-or fractional area change <math>&gt; 33\%</math> to <math>\leq 40\%</math></li> </ul> </li> </ul> <p><b>By MRI:</b></p> <ul style="list-style-type: none"> <li>•Regional RV akinesia or dyskinesia or dyssynchronous RV contraction</li> <li>•and 1 of the following:               <ul style="list-style-type: none"> <li>-Ratio of RV end-diastolic volume to BSA <math>\geq 100</math> to <math>\leq 110</math> mL/m<sup>2</sup> (male) or <math>\geq 90</math> to <math>\leq 100</math> mL/m<sup>2</sup> (female)</li> <li>-or RV ejection fraction <math>&gt; 40\%</math> to <math>\leq 45\%</math></li> </ul> </li> </ul>
Tissue characterization of wall	<ul style="list-style-type: none"> <li>•Residual myocytes <math>&lt; 60\%</math> by morphometric analysis (or <math>&lt; 50\%</math> if estimated), with fibrous replacement of the RV free wall myocardium in <math>\geq 1</math> sample, with or without fatty replacement of tissue</li> </ul>	<ul style="list-style-type: none"> <li>•Residual myocytes <math>60\%</math> to <math>75\%</math> by morphometric analysis (or <math>50\%</math> to <math>65\%</math> if estimated), with fibrous replacement of the RV free wall myocardium in <math>\geq 1</math> sample, with or without fatty replacement of tissue</li> </ul>

# Revised task force criteria for diagnosing arrhythmogenic right ventricular dysplasia

Diagnostic feature	Major criteria	Minor criteria
	<ul style="list-style-type: none"> <li>Inverted T waves in right precordial leads (V1, V2, V3)</li> </ul>	<ul style="list-style-type: none"> <li>Inverted T waves in leads V1 and V2 in individuals &gt;14 years of age (in the absence of bundle branch block)</li> </ul>
<p><b>•The diagnosis of ARVD is based on the presence of two major, one major and two minor, or four minor criteria</b></p> <p><b>•Due to the significant heterogeneity in the manifestation of disease, there is no single gold standard test to make the diagnosis of ARVD</b></p> <p><b>•Despite being quite specific, these TF criteria lacked sensitivity for diagnosis, especially in presymptomatic patients</b></p>		
	<ul style="list-style-type: none"> <li>Bradycardia of LBBB morphology with superior axis (negative or indeterminate QRS in leads II, III, and aVF and positive in lead aVL)</li> </ul>	<ul style="list-style-type: none"> <li>End of the QRS, including R, in V1, V2, or V3, in the absence of complete RBBB</li> <li>Nonsustained or sustained ventricular tachycardia of RV outflow configuration, LBBB morphology with inferior axis (positive QRS in leads II, III, and aVF and negative in lead aVL) or of unknown axis</li> <li>&gt;500 ventricular extrasystoles per 24 hours (Holter)</li> </ul>

FR 58Hz  
12cm

2D  
38%  
C 50  
P Low  
HGen



JPEG  
48 bpm

FR 55Hz  
13cm

2D  
45%  
C 50  
P Low  
HGen



JPEG  
\*\*\* bpm

FR 50Hz  
15cm

2D  
39%  
C 50  
P Low  
HGen



JPEG  
67 bpm

FR 55Hz  
13cm

2D  
44%  
C 50  
P Low  
HGen



JPEG  
\*\*\* bpm

# Clinical Manifestations

- **Palpitations: 67%**
- **Syncope: 32%**
- **Atypical chest pain: 27%**
- **Dyspnea: 11%**
- **Approximately 50% of patients with ARVD present with ventricular arrhythmias**
- **Most commonly sustained or nonsustained ventricular tachycardia that originates in the RV, therefore has a LBBB pattern if captured on EKG.**
- **VT can be exercised induced in patients with ARVD**

# Treatment

- Major goal is suppression of ventricular tachyarrhythmias (beta blockers)
- Antiarrhythmic medications (sotalol is usually first line agent)
- Avoid competitive sports
- Radiofrequency ablation
- European Society of Cardiology gave ICD placement class I recommendation for secondary prevention, class II a for primary prevention

# Stress-Induced Cardiomyopathy



# Classification (3)

## Cardiomyopathies

### HCM

#### Familial

- Sarcomere protein mutation
- Storage disease
- Disorders of fatty acid metabolism
- Carnitine deficiency
- Phosphorylase B kinase deficiency
- Mitochondrial cytopathies
- Syndromic HCM
- Others

#### Non-familial

- Obesity
- Infants of diabetic mothers
- Athletic training
- Amyloid (AL/prealbumin)

### DCM

#### Familial

- Sarcomere protein mutation
- Z-band
- Cytoskeletal genes
- Nuclear membrane
- Mildly dilated CM
- Intercalated disc protein mutations (see ARVC)
- Mitochondrial cytopathy

#### Non-familial

- Myocarditis
- Kawasaki disease
- Eosinophilic (Churg Strauss syndrome)
- Viral persistence
- Drugs
- Pregnancy
- Endocrine
- Nutritional
- Alcohol
- Tachycardia myopathy

### ARVC

#### Familial

- Intercalated disc protein mutations
- Cardiac ryanodine receptor (RyR2)
- Transforming growth factor- $\beta$ 3 (TGF $\beta$ 3)

#### Non-familial

- Inflammation

### RCM

#### Familial

- Sarcomeric protein mutations
- Familial amyloidosis
- Desminopathy
- Pseudoxanthoma elasticum
- Haemochromatosis
- Anderson-Fabry disease
- Glycogen storage disease

#### Non-familial

- Amyloid (AL/prealbumin)
- Scleroderma
- Endomyocardial fibrosis
- Carcinoid heart disease
- Metastatic cancers
- Radiation
- Drugs (anthracyclines)

### Unclassified

#### Familial



- Left ventricular non-compaction
  - Barth syndrome
  - Lamin A/C
  - ZASP
  - $\alpha$ -dystrobrevin

#### Non-familial



- Tako Tsubo cardiomyopathy

# Case

- F/49
- She underwent diagnostic coronary angiography two times due to chest pain, which showed no significant lesion two years ago.
- Sudden dyspnea was developed during routine annual colonofiberscopy in July 2009





# Emergency Department




BP 145/84 mmHg, HR 83 bpm


Peak CK-MB/troponin- I = 21.3/2.5 ng/mL





# CAG findings






2009.7.24.

2009.7.28.

## Adrenal Mass






CT




I-123 MIBG scan









# A Broken Heart



- A 70 yo female without past medical Hx
- Near collapse and chest pain that occurred when she was informed that her husband of 45 years had died of heart failure and refractory ventricular arrhythmias
- ECG; minor anterior ST segment elevations and inferolateral ST depressions, which resolved after IV NTG
- Normal CAG
- Echo 3 months later was normal

*Circulation 1998;98:1349*



# Stress-Induced Cardiomyopathy

## ■ Early investigators

Postmenopausal women, emotional stress  
Differential diagnosis of ACS or NSTEMI  
Excellent prognosis

## ■ Physical stress as an important precipitant

acute medical illness; sepsis, hypoxemia  
surgery/procedures; sigmoidoscopy, ERCP, bronchoscopy,  
uneventful GI or cardiac surgery

## ■ Dyspnea, hypotension, ECG abnormality, O<sub>2</sub> desaturation

## ■ High mortality with sudden cardiac death and recurrence

# **Stress-Induced Cardiomyopathy**

## **: Mechanism**

**Coronary micro-circulation**

**Multi-vessel spasm**

**Catecholamine mediated  
cardiotoxicity**

**a Catecholamine and Neuropeptide Levels.\***

	Patients with Stress Cardiomyopathy (N=13)			Patients with Killip Class III Myocardial Infarction (N=7)			Normal Value
	Day 1 or 2	Day 3, 4, or 5	Day 7, 8, or 9	Day 1 or 2	Day 3, 4, or 5	Day 7, 8, or 9	
	<i>median (interquartile range)</i>						
<b>precursor (pg/ml)</b>							
<b>amines (pg/ml)</b>							
ne	1264 (916–1374)†	1044 (733–1118)†	348 (180–550)	376 (275–476)	330 (220–385)	275 (220–311)	37‡
phrine	2284 (1709–2910)†	1573 (1235–2589)†	1142 (525–1252)	1100 (914–1320)	829 (727–914)	541 (516–660)	169‡
e	111 (106–146)†	77 (63–110)	56 (47–77)	61 (46–77)	61 (61–77)	38 (30–61)	15‡
<b>metabolites (pg/ml)</b>							
ylacetic acid	2758 (2573–3077)	2598 (2354–2892)†	1345 (1194–1682)	1513 (1211–1648)	1228 (1026–1362)	1009 (908–1059)	1497‡
<b>metabolites (pg/ml)</b>							
	178 (140–187)	509 (385–789)	659 (590–738)§	106 (89–124)	203 (177–213)	205 (189–243)	59‡
rine	216 (130–319)	456 (229–569)	661 (551–696)§	160 (145–170)	196 (181–209)	271 (225–288)	55‡
<b>metabolite (pg/ml)</b>							
Y	186 (162–236)§	185 (158–214)†	136 (90–182)§	77 (60–90)	69 (61–71)	60 (40–65)	51¶
ic peptide	1033 (805–1783)§	450 (205–684)	142 (72–236)	264 (192–483)	268 (249–574)	297 (142–419)	10–93
<b>metabolite (pg/ml)</b>							

# SCMP in ICU Patients

## Ventricular Apical Ballooning Due to Severe Physical Stress in Patients Admitted to the Medical ICU\*

*Yong Park, MD; Soo-Jin Kang, MD; Jae-Kwan Song, MD; Duk Kim, MD; Chae Man Lim, MD; Duk-Hyun Kang, MD; and Joon-Kook Koh, MD*

**Results:** Of the 92 patients, 65 (71%) were men, and they had a mean ( $\pm$  SD) age of  $63 \pm 11$  years. LVAB was observed in 26 patients (28%), with a mean lowest ejection fraction of  $33 \pm 8\%$  (range, 19 to 46%). Compared with the 66 patients (72%) without LVAB, those with LVAB had a higher frequency of sepsis (62% vs 14%, respectively;  $p < 0.001$ ), a higher prevalence of hypotension on ICU admission, more frequent use of inotropic agents, and a higher frequency of cardiomegaly and pulmonary edema ( $p < 0.005$  for each). Sepsis was the only variable associated with the development of LVAB (odds ratio, 9.2; 95% confidence interval, 2.4 to 35.8;  $p < 0.001$ ). The development of Q-wave or ST-segment displacement was associated with LVAB, but the sensitivities were 12% and 19%, respectively. Serum creatine kinase level was elevated in 12 of 26 patients (46%) with LVAB. The normalization of this condition occurred in 20 of 26 patients (77%) a mean duration of  $7.4 \pm 5.6$  days later (range, 2 to 25 days). The mean 2-month survival rate was lower in patients with LVAB than in those without ( $71 \pm 6\%$  vs  $52 \pm 10\%$ , respectively;

## Apical Ballooning in MICU: Results

	AB (-) (n=66)	AB (+) (n=26)	P value
	63.3 ± 12	63.3 ± 10	0.968
sex	48 (73%)	17 (65%)	0.612
factor for atherosclerosis			
hypertension	24 (36%)	4 (15%)	0.077
smoking	29 (44%)	13 (50%)	0.647
diabetes	17 (26%)	9 (35%)	0.445
reason for intensive care			<0.001
hypoxia and respiratory failure	36 (55%)	10 (39%)	
myocardial infarction	9 (14%)	16 (61%)	
others	15 (31%)	0 (0%)	
CHF occurs	68.8 ± 22.4	82.6 ± 22.8	0.0062



# SCMP in a Tertiary Referral Hospital

## Outcomes of Patients with Stress-Induced Cardiomyopathy Diagnosed by Echocardiography in a Tertiary Referral Hospital


Hyung Lee, MD, Jae-Kwan Song, MD, Byung Joo Sun, MD, Hyung Oh Choi, MD, Jeong-Sook Seo, MD,  
Jin Oh Na, MD, Dae-Hee Kim, MD, Jong-Min Song, MD, Duk-Hyun Kang, MD, Jae-Joong Kim, MD,  
and Seong-Wook Park, MD, *Seoul, South Korea*

Over a 63-month period, 56 consecutive patients (median age and interquartile range = 64 years [range 45-85 years]) were identified. Women comprised 79% (44/56) of all patients. The triggering events were acute illness, including sepsis and hypoxemia in 29 patients (52%, group A), in-hospital surgery/procedure (30%, group B), and emotional stress in 10 patients (18%, group C). Chest pain was more frequently observed in group C (50%) than in groups A (14%) and B (6%) ( $P = .021$ ), whereas dyspnea was the leading symptom in groups A and B. Typical takotsubo and inverted takotsubo were observed in 48 and 8 patients, with a median ejection fraction of 33%. Other abnormalities included dynamic LV outflow tract obstruction ( $n = 2$ ), LV thrombus ( $n = 2$ ), and right ventricular dysfunction ( $n = 12$ ). Nine deaths (16%) occurred during hospitalization. The groups did not differ in mortality. The Acute Physiology and Chronic Health Evaluation score (odds ratio 1.405; 95% confidence interval, 1.091-1.810;  $P = .009$ ) and absence of LV function within 1 week (ejection fraction  $< 50\%$ ) (odds ratio 14.080; 95% confidence interval, 1.184-167.475;  $P = .002$ ) were independent factors associated with mortality. During clinical follow-up up to 6 months, 3 more patients died, 2 of whom had recurrences of SIC.



# SCMP in a Tertiary Referral Hospital


56 consecutive patients in AMC  
Median age 64 years (52 – 74)  
Female 44 patients (79%)  
Three triggering events



# SCMP in a Tertiary Referral Hospital

6M mortality 13/56 (23%)

Associated factors: RV dysfunction &  
APACHE score



# Summary

## Classification of cardiomyopathy

- 1995 WHO classification
- 2008 ESC classification
- Will be continued.....

## Noncompaction cardiomyopathy

- NCCM shares disease genes and pathophysiological mechanisms with DCM and HCM
- Diagnostic criteria of NCCM
- Comorbid conditions

# Summary

## ARVC

- Diagnostic criteria
- Genetics
- Risk stratification & ICD insertion

## SCMP

- Unknown etiology
- Variable clinical situation
- Multiple RWEMAs mimicking ACS
- Variable clinical course !!

**Thank you for attention !!!**